George M Jenkins bought $500K of Palvella Therapeutics (PVLA)
Executed Feb 27, disclosed Mar 2, 3 days later.
Over the 21 trading sessions from the disclosed entry session (Mar 2), the stock returned -21.8% (delay-adjusted); from the execution session (Feb 27), -23.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
George M Jenkins (Director) filed 2 Form 4 reports in the trailing twelve months (1 purchase, 1 sale), most often in Palvella Therapeutics, Inc. (PVLA). Across 1 priced purchase filing, the average 21-session return was -23.3% from execution and -21.8% from disclosure (delay-adjusted; derived). The largest single filing was $4.0M of PVLA (26,677 sh across 7 lots, as filed), executed Sep 11.
Healthcare · Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→26,677 sh across 7 lots
Exec Sep 11
Filed Sep 15 · 9:15 PM ET